ClinicalTrials.gg
CompletedNCT03300518Updated Jan 11, 2022

Effectiveness of Estradiol Valerate Pretreatment in Antagonist Protocol for Poor Ovarian Response Patient

An interventional study of Follitropin Beta;MSD and Ganirelix in Infertility, sponsored by Reproductive & Genetic Hospital of CITIC-Xiangya. Completed at 1 site in China. Open to female participants aged 40 Years to 45 Years. Per ClinicalTrials.gov, last updated 2022-01-11.

Sponsored by Reproductive & Genetic Hospital of CITIC-Xiangya · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
552
Allocation
Randomized
Ages
40 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing estradiol in Infertility — 2 open to participants now, 2 under way, none of them phase 3. Estradiol · Infertility.

Enrollment
5th of 22
552 · median 155
Started
2017
with 1 other
No phase
8 of 22
none open now
Registered
16th of 22
by date

Among the 22 studies testing estradiol in Infertility, this one is the 5th largest by enrollment, is one of 2 that started in 2017, is one of 8 with no phase, and was the 16th registered.

Infertility

2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

2 of the 22 studies testing estradiol in Infertility are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About estradiol

Estradiol: first FDA approval 1954 (DELESTROGEN), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 40 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing estradiol in Infertility, or all of them as a file.
02

Study summary

The purpose of study is to assess the efficacy of add-on estrogen pretreatment in GnRH antagonist protocol on oocyte retrieval as compared with GnRH antagonist protocol for patients with poor ovarian response Add-on estrogen pretreatment protocol is superior to none pretreatment GnRH antagonist protocol for the number of oocytes retrieval

Read the detailed description

Women of advanced maternal age seeking ART treatment are characterized as poor ovarian responders in the process of ovarian simulation. Poor response to ovarian stimulation causes high cycle cancellation rate and extremely low pregnancy rate.

More attention has been paid to the potential interest of steroid pretreatments in GnRH antagonist cycles; not only for scheduling the GnRH antagonist cycles, but also for synchronizing the follicular growth which may result in more oocytes retrieved. But available clinical results are controversial.

Previous studies have shown that utilizing the natural negative feedback of the hypothalamus-pituitary-ovary axis induced by estradiol valerate pretreatment effectively prevented inter-cycle increases in follicle-stimulating hormone, improved follicle synchronization, and resulted in a more coordinated follicular development, leading to the recovery of more mature oocytes. However none of the randomized controlled studies compared estradiol valerate pretreatment or not on treatment outcomes, ongoing pregnancy rate, directly on poor response patients using estradiol valerate pretreatment in GnRH antagonist protocol.

03

Conditions studied

  • Infertility

Browse trials for

Keywords

  • GnRH antagonist
  • Estrogen pretreatment
  • Poor response patient
04

Who can participate

Ages eligible
40 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:Bologna criteria

  • At least two of the following three features must be present:

    1. Advanced maternal age (≥40 years) or any other risk factor for POR
    2. A previous POR (≤3 oocytes with a conventional stimulation protocol)
    3. An abnormal ovarian reserve test (i.e. antral follicle count \< 5-7 follicles or AMH\< 0.5 - 1.1 ng/mL)

Exclusion Criteria:

  1. Age ≥45 years,
  2. Patients who conducted PGD/PGS, and donor egg cycles were excluded.
  3. Presence of unilateral ovary absence
  4. Abnormal uterine deformity or structure.
  5. Spontaneous abortion patients with three or more (including biochemical pregnancy abortion)
  6. With other endocrine disease, ovulation disorders such as adrenal cortex function or thyroid dysfunction
  7. Have assisted reproductive technology or pregnancy contraindication of patients
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
552 participants (actual)

Study arms

  • Other
    pretreatment group

    the pretreatment group underwent a modified treatment protocol with pretreatment with estogen administering during the cycle preceding the IVF/ICSI cycle. daily dose of 4 mg (2 mg twice a day) estradiol valerate was given orally in the middle luteal phase which is confirmed seven days after ovulation monitoring by the ultrasound up to 2 days of the next menstrual cycle.Recombinant FSH (Puregon) was initiated on menstrual cycle day 2- 3 at an initial dose of 300 IU/day.A daily administration of ganirelix (0.25 mg Orgalutran; Organon) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger.

    Drug: Follitropin Beta;MSD · Drug: Ganirelix · Drug: hCG · Drug: estradiol valerate

  • Other
    control groups

    In the control groups standard GnRH-antagonist protocol was applied.Recombinant FSH (Puregon) was initiated on menstrual cycle day 2- 3 at an initial dose of 300 IU/day.A daily administration of ganirelix (0.25 mg Orgalutran; Organon) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger.

    Drug: Follitropin Beta;MSD · Drug: Ganirelix · Drug: hCG

Interventions

  • Patients will start stimulation with a daily s.c. injection of follitropin beta( 300IU Puregonon;MSD) menstrual cycle day 2 or 3.

    Also known as: Puregon

  • A daily administration of ganirelix (0.25 mg Orgalutran; MSD) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.

    Also known as: Orgalutran

  • DrughCG

    Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger

    Also known as: Ovidrel

  • Estradiol valerate (progynova,Schering) daily dose of 4 mg (2 mg twice a day) was given orally, started 7 days before the presumed onset of menses and administered up to 2 days of the next menstrual cycle

    Also known as: progynova

06

What researchers measure

Primary outcomes

  1. The number of oocytes retrieved by the IVG 36 hours after hCG administration

    The total MII oocytes retrievedd

    Time frame: 36 hours after hCG administration

Secondary outcomes

  1. Clinical pregnancy rate

    clinical pregnancy, defined as intrauterine pregnancy with a positive heartbeat at 6 weeks of gestation.Clinical pregnancy rate:Number of clinical pregnancies expressed per 100 initiated cycles, aspiration cycles, or embryo transfer cycles. When clinical pregnancy rates are given, the denominator must be specified.

    Time frame: 6weeks

  2. ongoing pregnancy rate

    ongoing pregnancy defined as an intact pregnancy at 12 weeks of gestation

    Time frame: 12weeks

  3. Optimal number of embryo

    According to the embryonic developmental rate and morphology, the high quality embryos were defined as the next day (D2) transplanted embryos reached 3 or 4 cells and the third day (D3) transplanted embryos reached 6 to 8 cells with morphological grade 1 or 2

    Time frame: 1 week

07

Study locations

1 site
  • Reproductive & Genetic Hospital of Citic-Xiangya
    Changsha, Hunan, China
08

References and documents

Publications

  • Zhang S, Tang Y, Wang X, Zong Y, Li X, Cai S, Ma H, Guo H, Song J, Lin G, Lu G, Gong F. Estrogen valerate pretreatment with the antagonist protocol does not increase oocyte retrieval in patients with low ovarian response: a randomized controlled trial. Hum Reprod. 2022 Jun 30;37(7):1431-1439. doi: 10.1093/humrep/deac081. PubMed 35460400 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Jun 2021, 43 months.

Of 386 non-industry interventional studies with no phase under Infertility, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's 43 months is above that.

Counting every sponsor, half of 416 studies reached it within 24 months; a quarter within 10 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2017
First posted
Oct 3, 2017
StartActual
Nov 15, 2017
Primary completionActual
Jun 18, 2021
CompletionActual
Aug 18, 2021
Last update
Jan 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03300518
Lead sponsor
Reproductive & Genetic Hospital of CITIC-Xiangya
Responsible party
Sponsor
First posted
Oct 3, 2017
Start date
Nov 15, 2017
Primary completion
Jun 18, 2021
Completion
Aug 18, 2021
Last update
Jan 11, 2022

Study contacts

Fei Gong, Doctor
study director · Reproductive & Genetic Hospital of CITIC-Xiangya

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Estradiol

Start the discussion